Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

July 13, 2021

TEVA PHARMACEUTICALS DEVELOPMENT, INC., v. AMICUS THERAPEUTICS U.S., INC.

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. September 03, 2021

    Teva Drops Claim That Rival Slowed Generic Development

    Teva Pharmaceuticals has voluntarily dropped its claims against Amicus Therapeutics Inc., which it had accused of hoarding supplies of a costly brand-name medication in violation of a new federal law aimed at providing generic drug manufacturers with predictable supplies of new medicines to aid in bringing unbranded alternatives to market.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login